Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Plus Therapeutics Inc PSTV

Healthcare Biotechnology
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers. The Company combines image-guided local beta radiation and targeted drug delivery approaches. The Company is advancing a pipeline of product candidates with lead programs in recurrent glioblastoma... see more

Recent & Breaking News (NDAQ:PSTV)

Cytori Therapeutics to Provide Corporate Update and Investor Presentation Live, at VirtualInvestorConferences.com September 10

Canada NewsWire September 3, 2015

Enrollment Begins in Cytori Phase III/Pivotal ADRESU Urinary Incontinence Trial

Business Wire September 3, 2015

Cytori Reports Second Quarter 2015 Business and Financial Results

Business Wire August 6, 2015

Enrollment Begins in Cytori U.S. Phase III/Pivotal Scleroderma Trial

Business Wire August 6, 2015

Japanese Approval Trial for Stress Urinary Incontinence Using Cytori Cell Therapy Announced

Business Wire July 30, 2015

Cytori Appoints VP of Business Development and General Counsel

Business Wire July 29, 2015

Cytori Licensee Kerastem Receives Conditional Approval from FDA for Alopecia Trial

Business Wire July 28, 2015

Cytori Second Quarter Financial Results Update

Business Wire July 27, 2015

Cytori Completes Enrollment in US Phase IIb Osteoarthritis Trial

Business Wire June 15, 2015

Cytori Therapeutics' Preclinical Data for the Treatment of Thermal Injury Published in the Journal Burns

Business Wire June 10, 2015

Cytori Restructures its Debt to a $17.7 Million Term Loan

Business Wire June 1, 2015

Cytori Reports First Quarter 2015 Business and Financial Results

Business Wire May 11, 2015

Cytori Prices Registered Direct Offering Providing for up to $25 million in Equity Financing

Business Wire May 5, 2015

Cytori First Quarter Financial Results Update

Business Wire April 30, 2015

Cytori Reports Preclinical and Mechanistic Data Supporting Use of Cytori Cell Therapy in Wounds Combining Thermal Burn and Radiation Exposure

Business Wire April 23, 2015

Cytori Provides Twelve Month Data Update on Scleradec-I Trial

Business Wire April 13, 2015

Cytori Granted Orphan Drug Status for Cellular Therapeutic in European Union

Business Wire April 7, 2015

Cytori and Lorem Vascular Receive Regulatory Clearance in China

Business Wire April 6, 2015

Cytori Launches Celase® GMP Product

Business Wire March 25, 2015

Biotech's Proprietary Tech. May Lead to New Treatments for Cancer

Accesswire March 24, 2015